Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
Por um escritor misterioso
Descrição
Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy - Frontiers
PDF) Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies
CD38 in the age of COVID-19: a medical perspective
AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice - eBioMedicine
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. - Abstract - Europe PMC
Evolving roles of CD38 metabolism in solid tumour microenvironment
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. - Abstract - Europe PMC
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. - Abstract - Europe PMC
de
por adulto (o preço varia de acordo com o tamanho do grupo)
